Tag: Cancer Drugs

Bayer got FDA approval for liver cancer drug

bayer
Bayer announced that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been pr...

Clinical studies of cancer drug by AbbVie are unsuccessful

abbvie
AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate -ribose) polymerase (PARP) inhibitor did...

Boehringer intends to create a new generation of immunotherapies

boehringer-ingelheim
Boehringer Ingelheim (BI) is aiming to develop a new generation of cancer immunotherapies, using vaccines, cancer-killing viruses and cell therapies combined with its own checkpoint inhibitor to attac...

The University of Queensland opens a new cancer research facility

cancer-diagnostics
New cancer-fighting drugs could emerge from The University of Queensland in coming years, thanks to a state-of-the-art imaging facility opened on March 28th at Brisbane, Quee...

NICE rejected pancreatic cancer treatment by Shire

shire
The UK’s National Institute for Health and Care Excellence (NICE) finalized its determination that Shire’s Onivyde treatment for advanced pancreatic cancer is not cost-effective, and should not be cov...

Lung cancer drug received approval in China

astrazeneca
AstraZeneca announced that the China Food and Drug Administration (CFDA) has granted marketing authorisation for Tagrisso (osimertinib) 40 mg and 80mg once-daily oral tablets for the treatment of adul...

A unique cancer drug can be tested in Russia soon

research
The scientists at the Institute of Chemical Biology and Fundamental Medicine (ICBFM) of the Siberian Branch of the Russian Academy of Sciences expect to receive in the near future the authorization fr...

Belarus researchers work on a new cancer drug

research
The researchers in Belarus are developing a new drug intended for liver and kidney cancer treatment. This was announced by Elena Kalinichenko, the Deputy Director for Science and Innovation at the Ins...

Lilly reported about clinical trial of breast cancer drug

lilly
Eli Lilly and Company announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase ...

Biocartis received €750,000 grant for MSI test development

research
Molecular diagnostics firm Biocartis won a €750,000 grant (approximately $796,000) from the Flanders Organization for Innovation & Entrepreneurship (VLAIO) to support the development of a fully au...

FDA approved Merck’s pembrolizumab

Merck
Merck / MSD announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of a...

Roche and Bavarian Nordic announced collaboration

roche
Bavarian Nordic A/S today announced an agreement with F. Hoffmann-La Roche Ltd  (Roche) whereby Roche has agreed to supply their PD-L1 blocking antibody Tecentriq (atezolizumab) for a clinical study c...

Novartis cancer drug approved by FDA

novartis
The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of pos...

Scripps Research Institute made a discovery in cancer treatment

scripps
Research conducted by The Scripps Research Institute has unearthed a potential treatment for those with prostate and breast cancer that specifically targets the cells without causing collateral damage...

New Russian cancer drug can make a revolution in oncology

research
In an interview to Izvestia newspaper, Professor Andrei Simbirtsev, Deputy Director of the Federal Medical-Biological Agency (FMBA) of Russia, Doctor of Medical Sciences, Corresponding Member of RAS, ...

Exelixis and Bristol-Myers Squibb announced the collaboration

bms
Exelixis, Inc. and Bristol-Myers Squibb Company announced the companies have entered into a clinical development collaboration to evaluate CABOMETYX™ (cabozantinib), Exelixis’ small molecule inhibitor...